Systemic Approach to Improving Treatment Outcome in Nasopharyngeal Carcinoma: Current and Future Directions

Overview

Journal Cancer Sci

Specialty Oncology

Date 2008 May 24

PMID 18498420

Citations 50

Authors

Brigette B Y Ma

Edwin P Hui

Anthony T C Chan

Affiliations

Soon will be listed here.

Abstract

Systemic therapy is an integral part of the management of non-keratinizing nasopharyngeal carcinoma (NPC). The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies have improved the treatment outcome for patients with NPC. Particular attention will be paid to the clinical application of chemotherapy in the adjunctive treatment of locoregionally advanced NPC, novel targeted drugs, Epstein-Barr virus-targeted vaccine therapies, and the use of plasma Epstein-Barr virus DNA as a biomarker for selecting patients for adjunctive therapies.

Citing Articles

Effects of Arctigenin in Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma 5-8F Cells.

Huang D, Lu R, Cai M, Meng J, He S, Zhang Q Anticancer Agents Med Chem. 2023; 23(10):1211-1216.

PMID: 36852795 PMC: 10332120. DOI: 10.2174/1871520623666230228155129.

M1 stage subdivisions based on F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma.

Qiu H, Zhang X, Liu S, Sun X, Mo Y, Lin H Ther Adv Med Oncol. 2022; 14:17588359221118785.

PMID: 35983026 PMC: 9379565. DOI: 10.1177/17588359221118785.

Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.

Alami I, Gihbid A, Charoute H, Khaali W, Brahim S, Tawfiq N Pan Afr Med J. 2022; 41:6.

PMID: 35145598 PMC: 8797042. DOI: 10.11604/pamj.2022.41.6.28946.

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.

Du C, Ni M, Jiang J, Kong F, Zhai R, Lv Y Eur Arch Otorhinolaryngol. 2022; 279(8):3947-3956.

PMID: 34981158 PMC: 9249729. DOI: 10.1007/s00405-021-07192-8.

Lipid-Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma.

Fu D, Li C, Huang Y Onco Targets Ther. 2021; 14:2449-2461.

PMID: 33859480 PMC: 8044085. DOI: 10.2147/OTT.S286813.

References

Taylor G, Haigh T, Gudgeon N, Phelps R, Lee S, Steven N . Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol. 2003; 78(2):768-78. PMC: 368843. DOI: 10.1128/jvi.78.2.768-778.2004. View

Chua D, Huang J, Zheng B, Lau S, Luk W, Kwong D . Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001; 94(1):73-80. DOI: 10.1002/ijc.1430. View

Yeo W, Leung T, Chan A, Chiu S, Yu P, Mok T . A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1999; 34(13):2027-31. DOI: 10.1016/s0959-8049(98)00280-9. View

Whitney B, Chan A, Rickinson A, Lee S, Lin C, Johnson P . Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol. 2002; 67(3):359-63. DOI: 10.1002/jmv.10073. View

. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on.... Int J Radiat Oncol Biol Phys. 1996; 35(3):463-9. DOI: 10.1016/s0360-3016(96)80007-1. View

Elser C, Siu L, Winquist E, Agulnik M, Pond G, Chin S . Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007; 25(24):3766-73. DOI: 10.1200/JCO.2006.10.2871. View

Ma B, Poon T, To K, Zee B, Mo F, Chan C . Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck. 2003; 25(10):864-72. DOI: 10.1002/hed.10307. View

Lo K, Huang D . Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12(6):451-62. DOI: 10.1016/s1044579x02000883. View

Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V . Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007; 43(9):1399-406. DOI: 10.1016/j.ejca.2007.03.022. View

10.

Langendijk J, Leemans C, Buter J, Berkhof J, Slotman B . The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22(22):4604-12. DOI: 10.1200/JCO.2004.10.074. View

11.

Airoldi M, de Crescenzo A, Pedani F, Marchionatti S, Gabriele A, Succo G . Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. Head Neck. 2001; 23(9):799-803. DOI: 10.1002/hed.1114. View

12.

Chua D, Ma J, Sham J, Mai H, Choy D, Hong M . Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006; 65(5):1300-6. DOI: 10.1016/j.ijrobp.2006.02.016. View

13.

Ngan R, Yiu H, Lau W, Yau S, Cheung F, Chan T . Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002; 13(8):1252-8. DOI: 10.1093/annonc/mdf200. View

14.

Chua D, Sham J, Au G . A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005; 41(6):589-95. DOI: 10.1016/j.oraloncology.2005.01.008. View

15.

Hong R, Ting L, Ko J, Hsu M, Sheen T, Lou P . Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19(23):4305-13. DOI: 10.1200/JCO.2001.19.23.4305. View

16.

Chua D, Sham J, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S . Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal.... Cancer. 1998; 83(11):2270-83. View

17.

Cheng S, Tsai S, Yen K, Jian J, Feng A, Chan K . Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(2):456-65. DOI: 10.1016/j.ijrobp.2004.05.047. View

18.

Chua D, Ma J, Sham J, Mai H, Choy D, Hong M . Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005; 23(6):1118-24. DOI: 10.1200/JCO.2005.12.081. View

19.

Dimery I, Peters L, Goepfert H, Morrison W, Byers R, Guillory C . Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol. 1993; 11(10):1919-28. DOI: 10.1200/JCO.1993.11.10.1919. View

20.

Bell A, Groves K, Kelly G, Croom-Carter D, Hui E, Chan A . Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol. 2006; 87(Pt 10):2885-2890. DOI: 10.1099/vir.0.81906-0. View